ArticleHuman vaccines & immunotherapeutics2017

The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model.

Ashleigh A McGirr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.